Interestingly, another study describes a correlation between a more active NFE2L2 pathway and a more favourable outcome in ER/PR positive breast cancer compared to triple negative breast cancer [29], similar to our results found in the ER positive subgroup of breast cancer patients. This evidence concerns the gene NFE2L2 and breast cancer.